Saraca Laboratories Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
- Paid Up Capital ₹ 8.00 Cr
- Company Age 37 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 21.90 Cr
- Satisfied Charges ₹ 1.51 Cr
- Revenue Growth -12.27%
- Profit Growth -161.91%
- Ebitda -710.86%
- Net Worth -19.69%
- Total Assets -13.91%
About Saraca Laboratories
Saraca Laboratories Limited (SLL) is a leading Public Limited Indian Non-Government Company incorporated in India on 11 January 1988 and has a history of 37 years and one month. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Suraca Laboratories P Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 8.00 Cr.
The company currently has active open charges totaling ₹21.90 Cr. The company has closed loans amounting to ₹1.51 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Saraca Laboratories Limited India is Shailesh Biradar as COMPANY SECRETARY. Lingareddy Venkata, Venkata Lingareddy, Puthana Subramanyam, and Five other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U85195TG1988PLC008172
- Company No.
008172
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Jan 1988
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Saraca Laboratories Limited offer?
Saraca Laboratories Limited offers a wide range of products and services, including API (Active Pharmaceutical Ingredients), Content Writing Service, Research Development Services, Online Education Consultancy Services, Career Guidance Centre, Product Engineering Service, Pilot Plants, Product Engineering and Prototyping, Digestive System Drugs & Medicines, Anti Ulcer Drugs.
Who are the key members and board of directors at Saraca Laboratories?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Puthana Subramanyam  | Managing Director | 16-Dec-1994 | Current |
| Shailesh Biradar | Company Secretary | 11-Jun-2019 | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mundla Vishnu | Director | 17-Feb-2006 | Current |
| Lingareddy Venkata | Whole-Time Director | 03-Mar-1992 | Current |
| Venkata Lingareddy | Director | 06-Apr-2000 | Current |
| Sree Mallidi | Director | 09-May-1997 | Current |
| Hemanth Nandigala | Director | 04-Nov-2014 | Current |
| Prasanth Nandigala | Director | 04-Nov-2014 | Current |
Financial Performance of Saraca Laboratories.
Saraca Laboratories Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.27% decrease. The company also saw a substantial fall in profitability, with a 161.91% decrease in profit. The company's net worth observed a substantial decline by a decrease of 19.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saraca Laboratories?
In 2023, Saraca Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mukunda Dairy Products Private LimitedLingareddy Venkata, Venkata Lingareddy and 1 more are mutual person
Max Infra (I) Private LimitedSree Mallidi is a mutual person
Pokarna LimitedPrasanth Nandigala is a mutual person
Virchow Petrochemical Private LimitedLingareddy Venkata, Prasanth Nandigala and 1 more are mutual person
- Virchow Laboratories Limited
Lingareddy Venkata, Venkata Lingareddy and 4 more are mutual person
- Virchow Drugs Limited
Lingareddy Venkata and Prasanth Nandigala are mutual person
Charges (Loans)
₹21.90 Cr
₹1.51 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 21.50 Cr
- Hdfc Bank Limited : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Aug 2022 | Hdfc Bank Limited | ₹3.96 M | Open |
| 30 Aug 1994 | State Bank Of India | ₹21.50 Cr | Open |
| 28 Mar 2000 | State Bvank Of Hyderabad | ₹0.40 M | Satisfied |
| 16 Mar 2000 | State Bank Of Hyderabad | ₹5.00 M | Satisfied |
| 19 Apr 1996 | State Bank Of Hyderabad | ₹4.70 M | Satisfied |
How Many Employees Work at Saraca Laboratories?
Saraca Laboratories has a workforce of 409 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saraca Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saraca Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
